دورة المؤشرنت للتحليل الفني
50 دينار كويتي
توصية شراءmyog
- بادئ الموضوع تريليوني
- تاريخ البدء
مبروك لملاك هذا السهم مع انه ادري محد ما عنده هذا السهم 
السهم اقفل علي سعر 35$ يوم الجمعه واليوم راح يكون الافتتاح عن مشارف ال 52$
علي فكره ليست توصيه شراء
Gilead Sciences (GILD) and Myogen (MYOG) announce that Gilead plans to acquire Myogen. The transaction has been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed by a cash merger in which Gilead would acquire any remaining outstanding Myogen common stock at $52.50 per share. Upon completion of the second-step merger, Myogen will become a wholly-owned subsidiary of Gilead. The value of the transaction is approximately $2.5 bln. The deal is expected to be dilutive to Gilead's earnings in 2007 and 2008, neutral in 2009 and accretive in 2010 and beyond. Myogen currently expects to file an NDA with the U.S. Food and Drug Administration as early as the fourth quarter of 2006. Ambrisentan has been granted orphan drug status for the potential treatment of PAH in both the United States and Europe. GlaxoSmithKline holds rights to the product outside the United States
السهم اقفل علي سعر 35$ يوم الجمعه واليوم راح يكون الافتتاح عن مشارف ال 52$
علي فكره ليست توصيه شراء
Gilead Sciences (GILD) and Myogen (MYOG) announce that Gilead plans to acquire Myogen. The transaction has been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed by a cash merger in which Gilead would acquire any remaining outstanding Myogen common stock at $52.50 per share. Upon completion of the second-step merger, Myogen will become a wholly-owned subsidiary of Gilead. The value of the transaction is approximately $2.5 bln. The deal is expected to be dilutive to Gilead's earnings in 2007 and 2008, neutral in 2009 and accretive in 2010 and beyond. Myogen currently expects to file an NDA with the U.S. Food and Drug Administration as early as the fourth quarter of 2006. Ambrisentan has been granted orphan drug status for the potential treatment of PAH in both the United States and Europe. GlaxoSmithKline holds rights to the product outside the United States
دورة المؤشرنت للتحليل الفني
50 دينار كويتي